Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant is performing well in terms of financials with a reported loss per share of $0.73 in 4Q26, slightly higher than the estimated and street consensus. With strong data and validation of their anti-FcRn mechanism, a potential FDA approval for IMVT-1402 would likely drive revenue of $749M, providing good potential for growth in the next few years. However, there are risks involved, mainly regarding regulatory and clinical approval, the impact of COVID-19 on clinical development, and the competitive market for their first product launch. Overall, the financials and potential market opportunity for Immunovant make it a promising stock for investors with a higher risk tolerance.

Bears say

Immunovant is positioned to address autoimmune diseases with their lead candidate IMVT-1402, an FcRn inhibitor. Their ongoing Phase 2 study has shown high efficacy in Period 1, and the company has enough cash to support operations through the potential launch of IMVT-1402 in generalized dermatomyositis, making them an attractive prospect. However, the statis

Immunovant Inc (IMVT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 8 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Jun 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.